Intellia Therapeutics, Inc.
NTLAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIntellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. At a $1.57B market cap, Intellia Therapeutics, Inc. ranks as a small-cap company within healthcare. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing.
Market Cap
$1.57B
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-4.37
EPS (TTM)
$-3.37
EPS (Fwd)
$-2.56
ROE
-55.4%
ROA
-30.1%
Cash
$437.8M
Total Debt
$73.4M
Free CF
-$249.8M
52W Change
-56.2%
Annual Financials
Cash vs Debt
Where NTLA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, NTLA finished 13.02% below its 150-day moving average ($13.13) and 12.15% below its 200-day moving average ($13.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTLA overbought or oversold?
At the October 19, 2026 close, NTLA's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intellia Therapeutics, Inc. holds $437.8M in cash against $73.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$249.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $33.1M (2021) to $67.7M (2025), reflecting a 105% increase over the period.
A beta of 1.80 means NTLA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NTLA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NTLA.